Tenaya Therapeutics Enters into Collaboration with Alnylam to Discover New Genetic Targets for Cardiovascular Disease
Friday, March 06, 2026
Tenaya Therapeutics has entered into a research collaboration agreement with Alnylam Pharmaceuticals to identify and validate novel human genetic targets for the development of disease-modifying therapies for cardiovascular diseases.
Under the terms of the agreement, Tenaya will validate up to 15 gene targets over a two-year period. The company will receive an upfront payment of up to $10 million and reimbursement for related research costs during the validation phase.
Alnylam will take responsibility for the development and commercialisation of any therapeutics that emerge from the identified targets. If all targets lead to approved therapies, Tenaya could receive up to $1.13 billion in development and commercial milestone payments.
Tenaya has developed integrated capabilities for identifying and validating potential therapeutic targets based on human genetics. These include the use of human induced pluripotent stem cell-derived cardiomyocytes combined with high-throughput in vitro screening, imaging analysis and machine learning tools to detect promising genetic targets.
The company also uses engineered human heart tissue and preclinical in vivo disease models to validate and study potential treatment candidates. Through these technologies, Tenaya has identified more than 150 genetic targets and supported the development of several programmes in its pipeline, including the gene therapies TN-201 and TN-401 and the small-molecule candidate TN-301, along with other early-stage projects.
Source: tenayatherapeutics.com
